Here are 1-3 brief analogies for Artelo Biosciences (ARTL):

• Think of Artelo Biosciences as a small, clinical-stage GW Pharmaceuticals (famous for Epidiolex), but developing synthetic drugs that modulate the endocannabinoid system for conditions like cancer anorexia, IBD, and PTSD.
• It's like an early-stage Sage Therapeutics (a neuroscience biotech) but with its entire drug development focused on unlocking the therapeutic potential of the body's endocannabinoid system for various unmet medical needs.

```html

• ART27.13: A synthetic G protein-coupled receptor agonist in clinical trials for treating anorexia associated with cancer and cancer cachexia.
• ART12.11: A synthetic cannabidiol cocrystal being developed for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD).
• ART26.12: A fatty acid binding protein 5 inhibitor currently under development for treating prostate and breast cancer, as well as PTSD.

```

Artelo Biosciences (ARTL) is a clinical-stage biopharmaceutical company focused on developing treatments to modulate the endocannabinoid system. Its product candidates are currently in various phases of clinical trials, such as Phase 1b/2a for ART27.13.

Given its stage of development, Artelo Biosciences does not currently have commercialized products on the market and, therefore, does not have major customers in the traditional sense of selling pharmaceutical products or services.

null

null

Here are the key risks to Artelo Biosciences:

1. Risk of Clinical Trial Failure or Delays: As a clinical-stage biopharmaceutical company, Artelo Biosciences' success is heavily dependent on the successful and timely completion of its clinical trials for product candidates such as ART27.13, ART12.11, and ART26.12. Clinical trials are inherently uncertain, costly, and have a high rate of failure, with less than 12% of candidate drugs making it to market. Delays or failures in any phase of these trials could significantly harm the company's prospects and financial viability.
2. Risk of Financial Distress and Inadequate Funding: Artelo Biosciences faces significant financial challenges, reporting ongoing net losses and possessing minimal cash and investments. The company's financial health indicators, including a low current ratio and negative equity, suggest liquidity constraints and financial distress. Auditors have raised "going concern" doubts, indicating a risk of operational failure without immediate capital infusion. The company's ability to fund its ongoing and future clinical programs is highly dependent on securing additional financing, which could lead to further stock dilution.
3. Risk of Failure to Obtain Regulatory Approval: Even if Artelo Biosciences' product candidates successfully complete clinical trials, there is no guarantee of obtaining the necessary regulatory approvals (e.g., from the FDA) for commercialization. The regulatory approval process is rigorous, complex, and can be lengthy, involving significant administrative burden and adherence to manufacturing standards. Failure to secure these approvals would prevent the company from bringing its drugs to market, severely impacting its ability to generate revenue.

null

Artelo Biosciences (symbol: ARTL) is developing treatments for several conditions with significant addressable markets:

• ART27.13 (Anorexia associated with cancer / Cancer Cachexia):
  • The global cancer cachexia market was estimated at approximately $2.54 billion in 2024 and is projected to reach $3.90 billion by 2033. North America held the largest share of 42.73% of the global market in 2024. Another estimate places the global cancer cachexia market at $2.2 billion in 2024, growing to $3.0 billion by 2033. For cancer anorexia specifically, the global market is valued at approximately $1.2 billion in 2024 and is projected to reach around $2.5 billion by 2034. The market size for cancer anorexia in the United States was approximately $131 million in 2023.
• ART12.11 (Inflammatory bowel disease and Post-traumatic stress disorder):
  • The global inflammatory bowel disease treatment market was valued at $26.6 billion in 2024 and is expected to grow to $47.3 billion by 2034. The U.S. inflammatory bowel disease treatment market reached $16.6 billion in 2024. North America is anticipated to lead the inflammatory bowel disease market in 2025, with approximately 49.6% market share.
  • The global post-traumatic stress disorder (PTSD) treatment market is calculated at $2.37 billion in 2025 and is projected to reach approximately $3.55 billion by 2035. North America dominated the global market with the largest market share of 58% in 2025. The United States accounted for approximately 90% of the total PTSD market size in the 7MM (United States, EU4, UK, and Japan) in 2024.
• ART26.12 (Prostate cancer and Breast cancer):
  • The global prostate cancer therapeutics market was valued at $12.6 billion in 2024 and is expected to reach $29.9 billion by 2034. In 2024, the North America region accounted for 39.2% of the global market. The U.S. prostate cancer therapeutics market was valued at $4.3 billion in 2023.
  • The global breast cancer therapeutics market size was valued at $29.85 billion in 2023 and is anticipated to reach around $60.78 billion by 2033. North America dominated the global breast cancer therapeutics market with a 37% share in 2023. The U.S. breast cancer therapeutics market size reached $7.98 billion in 2023 and is anticipated to surpass around $16.33 billion by 2033.

Artelo Biosciences (ARTL), a clinical-stage biopharmaceutical company, is poised for potential revenue growth over the next 2-3 years primarily through the advancement of its product pipeline and the securing of strategic partnerships. As of early 2026, the company's revenue growth is expected to be driven by key clinical and commercial milestones for its lead product candidates: ART27.13, ART26.12, and ART12.11. Here are 3-5 expected drivers of future revenue growth for Artelo Biosciences: * Potential Commercialization or Significant Partnership for ART27.13 in Cancer Anorexia-Cachexia Syndrome (CACS): Artelo Biosciences announced positive interim Phase 2 results for ART27.13 in treating cancer anorexia-cachexia syndrome (CACS) in September 2025, demonstrating improvements in weight gain, lean body mass, and activity, along with a favorable safety profile. Given that there is currently no FDA-approved treatment for CACS, the company is actively seeking partnerships to advance ART27.13 into Phase 3 trials. A successful partnership could involve substantial upfront and milestone payments, and potentially lead to initial product sales or royalties within the 2-3 year timeframe, aligning with analyst forecasts of significant revenue for Artelo Biosciences in 2028. The European Patent Office has also allowed a patent for ART27.13's commercial formulation, extending protection through December 2041, which strengthens its commercial potential and attractiveness to partners. * Advancement of ART26.12 into Later-Stage Clinical Trials and Potential Partnerships: Following positive Phase 1 single ascending dose (SAD) study results in February 2026, Artelo Biosciences plans to initiate a Phase 2 multiple ascending dose (MAD) study for ART26.12 in the third quarter of 2026. ART26.12 is being developed for chemotherapy-induced peripheral neuropathy (CIPN), with potential applications in osteoarthritis pain, other cancer-related pain, psoriasis, and anxiety. Successful progression through these clinical stages could attract significant licensing or collaboration agreements, providing revenue through milestone payments as the program moves closer to potential commercialization. * Expedited Clinical Development and Partnership for ART12.11: Artelo Biosciences received favorable regulatory guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ART12.11, supporting Phase 1 study plans and potential accelerated pathways. The company plans to initiate human clinical studies with an oral solid dosage form in the first half of 2027, contingent on toxicology results in 2026. Preclinical data has shown ART12.11 to have improved pharmacokinetics and efficacy compared to standard cannabidiol (CBD), including robust antidepressant-like activity. The potential for an accelerated development strategy, coupled with strong preclinical evidence and patent protection until December 2038, could lead to early-stage partnerships that generate revenue through upfront payments or development milestones within the next 2-3 years. * Strategic Licensing and Collaboration Agreements Across the Pipeline: As a clinical-stage biopharmaceutical company with multiple promising candidates addressing significant unmet medical needs, Artelo Biosciences is well-positioned to secure non-dilutive funding through strategic licensing agreements or collaborations for any of its pipeline assets. Such agreements are a common and vital source of revenue for companies at this stage, typically involving upfront payments upon signing, milestone payments tied to clinical development and regulatory achievements, and future royalties on product sales if successful. The company has explicitly stated that positive clinical progress and intellectual property position have advanced partner interest in its programs.

Share Issuance

• Artelo Biosciences conducted an underwritten public offering in September/October 2025, generating approximately $2.0 million in gross proceeds.
• A one-for-six (1-for-6) reverse stock split was effected on June 13, 2025, reducing the number of outstanding shares from 3.28 million to approximately 546,667, primarily to meet Nasdaq listing requirements.
• A 3-for-1 reverse stock split was approved on February 27, 2026, and became effective on March 10, 2026, to enhance share price and marketability, resulting in approximately 708,258 shares issued and outstanding immediately after the split.

Inbound Investments

• Artelo Biosciences has received "meaningful partnering interest" from several pharmaceutical companies following positive interim Phase 2 data for ART27.13 in cancer-related anorexia.
• Partnering interest for ART26.12, a FABP5 inhibitor, continues to expand.
• The company received £1.3 million in UK tax credits in 2024.

Capital Expenditures

• Research and development (R&D) expenses, representing the primary capital allocation for advancing the pipeline, were $5.4 million for the year ended December 31, 2025.
• R&D expenses were $6.0 million for the year ended December 31, 2024.
• The primary focus of these expenditures is on advancing Artelo's clinical pipeline, including programs like ART27.13 for cancer anorexia, ART26.12, and ART12.11.